* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download What`s hiding behind IgA nephropathy?
Atherosclerosis wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Anti-nuclear antibody wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Kawasaki disease wikipedia , lookup
Graves' disease wikipedia , lookup
Complement system wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Pathophysiology of multiple sclerosis wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Behçet's disease wikipedia , lookup
Globalization and disease wikipedia , lookup
Germ theory of disease wikipedia , lookup
Ankylosing spondylitis wikipedia , lookup
Neuromyelitis optica wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Rheumatoid arthritis wikipedia , lookup
What’s hiding behind IgA nephropathy? Case Report Bauerova L., Honsova E. Department of Pathology, the The First faculty of Medicine and General Teaching Hospital, Charles University Prague Nephropathology training: Department of Clinical and Transplantant Pathology, IKEM Clinical history: • • • • • 31– year – old woman Proteinuria, fatigue, edema of the hands Tinnitus and sudden hearing loss of the left ear Arterial hypertension Nephrotic proteinuria (5g/day) and microscopic hematuria • Serum creatinine level of 73μmol/l (0,79mg/dl) • Audiometry → hearing abnormalities • Immunology was negative (ELISA testing – IgA, IgM, IgG, C3 and C4 complement, extractable nuclear antigen (ENA), antinuclear antibodies (ANA), ds-DNA antibodies, ANCA, rheuma factor). IgA Diagnosis: IgA nephropathy + suspicious Fabry´s disease ↓ Genetic testing was recommended ↓ (Low -galactosidase A activity in plasma and leucocytes) + Heterozygous mutation of α-Gal A gene Aberrantly glycosylated IgA1 IgA nephropathy Complement components Production of antiglycan antibodies IgG-IgA1, IgA1-IgA1 complexes • Proliferation of mesangial cells • Expansion of ECM • Cytokines and growth factors production • Local complement activation Fibronectin Type IV collagen Podocytes and tubular cells damage Fabry´s disease • • • • X-linked recessive lysosomal storage disorder Deficient activity of α-galactosidase A Clinical manifestations are variable Skin lesions, corneal dystrophy, paresthesias and proteinuria • During adulthood: heart disease, premature cerebrovascular accidents, and progressive renal disease Fabry´s disease • The link between the metabolic abnormality in Fabry´s disease and kidney tissue injury is still unclear • In females, there are highly variable levels of enzyme activity and broader range of clinical symptoms • Most females are affected; in various studies, 12% of Fabry´s patients on dialysis are women In a kidney biopsy sample • Swollen, finely vacuolated podocytes in LM • Dark blue bodies in semi-thin sections embedded in epoxy resin • Osmiophilic, lamellar bodies mainly in podocytes (myelin figures, “zebra” bodies) in ELMI • All renal cells can be affected • Difficulties in cases with more advanced stages of FD A case for second opinion Differential diagnosis • Myelin-like inclusions are not entirely specific for Fabry´s disease • Long-term treatment with cationic amphiphilic drugs (chloroquine and amiodarone) • Chloroquine-induced lipidosis in the kidney is not so rare • Specific curvilinear inclusions in podocytes are not present in FD (Prof. Ferluga in his lecture, 23rd ECP, Helsinki 2011) Dusan Ferluga: Electron microscopy of Fabry nephropathy and drug-induced phospholipidosis. 23rd ECP, Helsinki 2011 The coexistence of IgA nephropathy and Fabry´s disease: • The coexistence of FD and immune disorders such as SLE, rheumatoid arthritis and pauciimmune and immune complex-mediated necrotizing crescentic glomerulonephritis has been described in the literature • The combination of FD and IgAN is rare Patient´s follow up: • Human α-galactosidase A replacement therapy • Antihypertensive drugs with diuretics • Cardiac function and blood pressure in the normal range • S-Cr: 65 μmol/l (0.71 mg/dl) • Proteinuria decreased (1g/day) • Peripheral edema disappeared • Still suffering from: fatigue, paresthesia, tinnitus, and hearing loss Thank You